Avantect

ClearNote Health is pleased to partner with Dr. Steve Edelman and the team at Taking Control Of Your Diabetes (TCOYD), a provider and patient advocacy group guided by the belief that every person with diabetes has the right to live a healthy, happy and productive life. TCOYD educates and motivates people to take a more active role in their condition by providing education to both medical professionals and patient communities caring for people with #diabetes.

📢 Press Release: Avantect Ovarian Cancer Test Receives CPT Code and Preliminary Payment Determination from the Centers for Medicare and Medicaid Services ClearNote Health has today announced the American Medical Association (AMA) has issued a new Current Procedural Terminology (CPT) Proprietary Laboratory Analyses (PLA) code for the Avantect Ovarian Cancer Test. Effective October 1, 2024, the new CPT code, 0507U, establishes a reimbursement pathway for increased patient access and broader test adoption. In addition, CMS announced that it has proposed preliminary reimbursement rate determinations for new and revised CPT codes issued by the American Medical Association (AMA), including 0507U for the Avantect Ovarian Cancer Detection Test. ClearNote Health aligned with CMS on their reimbursement recommendation of $1,160.00. “Receiving a CPT code and CMS preliminary rate recommendation for our Avantect Ovarian Cancer Test represents the second time ClearNote Health has reached a critical commercial and reimbursement milestone for our organization in less than 12 months, and most importantly, expands patient access to the early detection for ovarian cancer,” said Dave Mullarkey, CEO of ClearNote Health. 👉 Read the full press release on our website: https://lnkd.in/d-CyXp-d 🎓 The Avantect test is intended for patients at high risk for ovarian cancer, such as those with a genetic predisposed risk such as BRCA1, BRCA2, a family history of ovarian cancer, or a personal history of breast cancer before age 40. Learn more about the test on our website: https://lnkd.in/dDiNpaNr #ovariancancer #earlycancerdetection

⭐ New Publication Alert!   We’re excited that our latest research, titled “Analytical Validation of an Early Detection Pancreatic Cancer Test using 5-Hydroxymethylation Signatures,” has been published in the The Journal of Molecular Diagnostics.   Following the foundational work by Haan et al. (2023), this publication showcases the rigorous analytical validation of the Avantect Pancreatic Cancer Test. It details key performance metrics, including: > precision > stability > limit of detection (LOD) and compares Avantect to other methylation-based approaches.   This article underscores Avantect’s reliability and accuracy and adds to the growing evidence that Avantect meets the high-quality standards required for clinical testing.   👉 Read the full publication here: https://lnkd.in/dQpz5nhe 🖥 Alternatively, visit our website to learn about the wide range of published research that supports our innovative, #epigenomics based technology: https://lnkd.in/dcadUKsH   #ClearNoteHealth #PancreaticCancer #EarlyDetection

🔥 Great energy here at the American Diabetes Association's 84th Scientific Sessions, #ADA2024! ⚡ 👉 Stop by the Avantect booth (#1154) to learn more about the increased risk for pancreatic cancer in the new-onset type 2 diabetes #t2dM population. Avantect’s non-invasive test allows for early detection of pancreatic cancer from a simple blood draw. ⭐ Learn more or contact us at https://lnkd.in/g_YvPCdt. ⭐

📢 🎓 We are on a mission to help improve awareness around the risks for #pancreaticcancer. Take part in our survey and help spread knowledge. If you’re attending #ADA2024 stop by our booth #1154 and learn more about our non-invasive blood test, the Avantect Pancreatic Test, and how it is enabling a new paradigm of early detection of pancreatic cancer in high risk populations.    #ADAscisessions

Are you attending the American Diabetes Association's 84th Scientific Sessions, taking place in Orlando, FL, June 21-24? Don't miss our team at booth #1154!   ❗Are you aware that a new diagnosis of type 2 diabetes significantly increases the risk of #pancreaticcancer? The Avantect Pancreatic Cancer Test is a simple blood test designed to help make earlier diagnosis possible, offering an improved chance for successful treatment and longer survival.   👉 Visit our team at the event to learn more or contact us at https://lnkd.in/dH3XKJvS   #ADAscisessions

🌍 On May 17, 2024, ClearNote Health's CEO Dave Mullarkey traveled to Athens, Greece, solidifying our commercial partnership with GeneKor Medical S.A. to advance the field of early cancer detection. 👋 Hosted by Nikolaos Tsoulos of Genekor, our discussions centered on the rollout of the Avantect Pancreatic Cancer Test across multiple EU countries. This innovative diagnostic solution is poised to enhance early detection of pancreatic cancer in key Genekor territories.   👨⚕️During our visit, Dave also engaged with local Key Opinion Leaders to align on the best approaches to integrate this technology into their medical practice and healthcare systems effectively.   🤝This partnership underscores our shared commitment to pioneering advancements in healthcare and to significantly improving patient outcomes through state-of-the-art diagnostics.   We are inspired by the potential of our collaboration with Genekor and eagerly anticipate the impact our combined efforts will have on transforming cancer care globally. #earlycancerdetection #pancreaticcancer

🚨 Highlight from Abu Dhabi Global Health Week: Liquid Biopsy for Early Cancer Detection 🎤 At the Abu Dhabi Global Healthcare Week Week, Dave Mullarkey, CEO of ClearNote Health, showcased the groundbreaking Avantect Pancreatic Cancer Test. 🔈In a panel discussion led by Dr. Lawrence P Petalidis of M42 he focused on the test’s use of liquid biopsy technology for early detection in high-risk patients, including those recently diagnosed with Type 2 diabetes. 🌟 Highlighting the test’s potential, Dave illustrated how Avantect significantly enhances early cancer detection, offering advantages over traditional methods and paving the way for significantly increasing survival rates in pancreatic cancer. 🤝 The session was a clear testimony of how M42 Health, supported by the Department of Health Abu Dhabi and in close clinical collaboration with Cleveland Clinic Abu Dhabi, is pioneering advancements in oncology, driving the next generation of cancer diagnostics. #ADGHW #CancerDiagnostics #HealthcareInnovation #LiquidBiopsy

Over the weekend, members of our team took part in #PanCAN #PurpleStride San Diego 2024, which brought together pancreatic cancer survivors, families, caregivers, researchers and supporters. Within this decade, pancreatic cancer is expected to be the second leading cause of cancer mortality in the United States. However, it’s been shown that diagnosis at an early stage, when patients have better treatment options, has the potential to increase survival rates by more than ten times. We're proud to be helping raise awareness of the impact of #pancreaticcancer and contributing to better patient outcomes for this devastating disease.

🧬 Happy #DNADay! 🧁 Today, we celebrate the remarkable milestones in genetic discovery that have shaped our understanding of human health, from the completion of the Human Genome Project in 2003 to the groundbreaking discovery of DNA's double helix in 1953. At ClearNote Health, we're honored to be playing a part in this journey. Our team is reflecting on the progress made and celebrating our contributions. With our proprietary epigenomic platform and cell-free DNA-based assays, we're driving early cancer detection by analyzing dynamic biological changes at the cellular level. While there's much more to do, we're inspired by the potential of genetics to transform healthcare and improve lives. Here's to continued innovation! #GeneticDiscovery #Epigenomics #EarlyCancerDetection